Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Erasca (Nasdaq: ERAS) announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Management will present on Tuesday, January 13, 2026 at 1:30 PM PT, participate in one-on-one investor meetings, and provide a live audio webcast at Erasca.com/events. An archived replay will be available for 30 days after the webcast.
Positive
- None.
Negative
- None.
News Market Reaction – ERAS
In the Jan 6 session, ERAS gained 4.01%, reflecting a moderate positive market reaction. Argus tracked a peak move of +72.2% during that session. Our momentum scanner triggered 62 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 15.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conference | Positive | +6.2% | Evercore healthcare conference fireside chat and webcast announcement. |
| Nov 12 | Earnings update | Positive | +12.3% | Q3 2025 business update, patent issuance, cash runway into H2 2028. |
| Nov 06 | Patent issuance | Positive | +1.8% | U.S. patent issued covering pan‑RAS molecular glue ERAS‑0015. |
| Nov 04 | Conference schedule | Neutral | -2.9% | Multiple November 2025 investor conferences and fireside chats. |
| Sep 02 | Investor conference | Neutral | +1.9% | Morgan Stanley global healthcare conference presentation and meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ERAS often reacted positively to earnings and many conference-related updates, though some conference appearances produced muted or negative moves.
Over the past few months, Erasca has repeatedly highlighted its participation in major healthcare conferences and investor events, along with patent and earnings updates. An August 2025 strategic and financial update and a November 2025 earnings release both coincided with double‑digit positive moves. Patent protection for ERAS‑0015 through September 2043 and continued global conference visibility frame today’s J.P. Morgan appearance as part of an ongoing investor outreach and RAS/MAPK‑focused pipeline story.
Key Terms
ras/mapk pathway medical
oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California. Management will present on Tuesday, January 13, 2026, at 1:30 pm Pacific Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
